Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSV allogeneic bone marrow-derived mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Centre Hospitalier Universitaire de Montpellier
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intradiscal
01
Overview
MSV allogeneic bone marrow-derived mesenchymal stromal cells is an investigational cell therapy developed by the University Hospital of Montpellier for the treatment of chronic low back pain associated with degenerative disc disease (DDD). The product consists of mesenchymal stromal cells (MSCs) harvested from the bone marrow of healthy allogeneic donors and expanded in vitro under Good Manufacturing Practice (GMP) conditions. These cells are delivered via a single intradiscal injection into the affected intervertebral disc. The therapeutic mechanism is primarily paracrine, where the MSCs secrete a variety of anti-inflammatory cytokines, growth factors, and extracellular matrix precursors. This secretome helps to modulate the inflammatory environment within the disc, reduce pain, and potentially stimulate the regeneration of disc tissue. The therapy has been evaluated in clinical trials such as the multicenter RESPINE study.
- Other names
- allogeneic bone marrow-derived mesenchymal stromal cellsallogeneic BM-MSCs
Beyond the preview
Go deeper on MSV allogeneic bone marrow-derived mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSV allogeneic bone marrow-derived mesenchymal stromal cells.